Indeed, although in our MS population patients treated with DMTs possibly associated with dysautonomic side effects (IFNB, DMF, FTY) [13] showed similar median scores in comparison with untreated patients (Supplementary Table 5), subtle drug-dependent impairment of autonomic function cannot be excluded. The gene discussed is IFNB1; the disease is myeloid sarcoma.